Beijing Scitop Bio Tech Co Ltd (300858) - Total Assets
Based on the latest financial reports, Beijing Scitop Bio Tech Co Ltd (300858) holds total assets worth CN¥2.03 Billion CNY (≈ $296.66 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Beijing Scitop Bio Tech Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Beijing Scitop Bio Tech Co Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Beijing Scitop Bio Tech Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Beijing Scitop Bio Tech Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Beijing Scitop Bio Tech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Beijing Scitop Bio Tech Co Ltd's total assets of CN¥2.03 Billion consist of 48.4% current assets and 51.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 4.9% |
| Accounts Receivable | CN¥69.06 Million | 3.4% |
| Inventory | CN¥46.47 Million | 2.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥60.10 Million | 3.0% |
| Goodwill | CN¥1.91 Million | 0.1% |
Asset Composition Trend (2015–2025)
This chart illustrates how Beijing Scitop Bio Tech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Beijing Scitop Bio Tech Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Scitop Bio Tech Co Ltd's current assets represent 48.4% of total assets in 2025, a decrease from 80.6% in 2015.
- Cash Position: Cash and equivalents constituted 4.9% of total assets in 2025, down from 25.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 7.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 3.4% of total assets.
Beijing Scitop Bio Tech Co Ltd Competitors by Total Assets
Key competitors of Beijing Scitop Bio Tech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Beijing Scitop Bio Tech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.73 | 11.41 | 5.32 |
| Quick Ratio | 7.41 | 10.95 | 4.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥801.57 Million | CN¥979.39 Million | CN¥620.82 Million |
Beijing Scitop Bio Tech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Scitop Bio Tech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.67 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | 5.4% |
| Total Assets | CN¥2.02 Billion |
| Market Capitalization | $601.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Scitop Bio Tech Co Ltd's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing Scitop Bio Tech Co Ltd's assets grew by 5.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing Scitop Bio Tech Co Ltd (2015–2025)
The table below shows the annual total assets of Beijing Scitop Bio Tech Co Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.02 Billion ≈ $295.43 Million |
+5.39% |
| 2024-12-31 | CN¥1.92 Billion ≈ $280.31 Million |
+5.83% |
| 2023-12-31 | CN¥1.81 Billion ≈ $264.87 Million |
+1.09% |
| 2022-12-31 | CN¥1.79 Billion ≈ $262.01 Million |
+72.05% |
| 2021-12-31 | CN¥1.04 Billion ≈ $152.29 Million |
+4.15% |
| 2020-12-31 | CN¥999.25 Million ≈ $146.22 Million |
+114.44% |
| 2019-12-31 | CN¥465.97 Million ≈ $68.19 Million |
+24.68% |
| 2018-12-31 | CN¥373.74 Million ≈ $54.69 Million |
+10.77% |
| 2017-12-31 | CN¥337.39 Million ≈ $49.37 Million |
+26.71% |
| 2016-12-31 | CN¥266.26 Million ≈ $38.96 Million |
+44.27% |
| 2015-12-31 | CN¥184.55 Million ≈ $27.01 Million |
-- |
About Beijing Scitop Bio Tech Co Ltd
Beijing Scitop Bio-tech Co., Ltd. researches, develops, produces, and sells probiotic, postbiotics, and microecologival preparations for animals and plants in China. It provides probiotic and postbiotics for gastrointestinal health, immune regulation, oral health, sleep aid and stress relief, women's health, slimming and fat reduction, kidney and liver protection, blood sugar regulation, allergy … Read more